A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) (ADAPT-EARLY)
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis
Sponsor: argenx
A PHASE4 clinical study on New Onset Generalized Myasthenia Gravis (gMG), this trial is actively recruiting participants. The trial is conducted by argenx and has accumulated 9 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE4
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE4
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE4
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE4
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE4
▶ Show 4 earlier versions
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE4
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE4
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- argenx
For direct contact, visit the study record on ClinicalTrials.gov .